Ozurdex launched in China for RVO

Ozurdex launched in China for RVO

Colin Kerr

Published: Tuesday, May 1, 2018

Allergan has announced the launch of Ozurdex (dexamethasone intravitreal implant 0.7mg) in China for the treatment of adult patients with macular oedema secondary to retinal vein occlusion (RVO). Ozurdex is the first approved intravitreal injection for RVO in China and is licensed for the treatment of macular oedema following BRVO and CRVO. “Providing millions of RVO patients access to Ozurdex is a significant step towards preventing blindness and meeting a critical unmet need in China,” said Marc Princen, Allergan International President. http://www.allergan.com/

Latest Articles

ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Supplement: ESCRS Clinical Trends Series: Presbyopia

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.